14 results about "Tanshinone I" patented technology

The invention discloses a salvia miltiorrhiza endogenous oligopeptide composition and application thereof. The composition contains salvia miltiorrhiza endogenous oligopeptides miPEP167b-5p and miPEP171b-1, wherein the concentration ratio of the salvia miltiorrhiza endogenous oligopeptides miPEP167b-5p to the miPEP171b-1 is 0.8-1.2. The oligopeptide used in the composition has high species specificity, does not promote the growth of other plants in the field, and avoids the ecological risk of a traditional broad-spectrum growth regulator. Field experiment results show that after the composition is applied to treatment, the root system yield of salvia miltiorrhiza is increased by 56% compared with that of a control group, the number of roots is increased by 435% compared with that of the control group, the rosmarinic acid content is increased by 43% compared with that of the control group, the salvianolic acid B content is increased by 81%, the tanshinone I content is increased by 214%, the tanshinone IIA content is increased by 75%, the leap-type improvement of the salvia miltiorrhiza medicinal material yield and quality is synchronously achieved, and the application prospect is wide. And reliable technical support is provided for green, efficient and high-quality development of the salvia miltiorrhiza industry.

The invention discloses a method for detecting effective components of a radix salviae miltiorrhizae extracting solution based on a Raman spectrum and a neural network, and belongs to the field of analysis and detection. The detection method comprises the following steps: providing a salvia miltiorrhiza extracting solution sample; acquiring Raman spectrum characteristic data of the extracting solution sample; and inputting the Raman spectrum characteristic data into a quantitative detection model of the effective components of the salvia miltiorrhiza, and determining the concentrations of tanshinone I, tanshinone IIA and salvianolic acid B in the sample to be detected. The method has the advantages of being high in prediction precision (the correlation coefficient R2 reaches 0.98), high in universality and free of destructiveness, and is suitable for rapid quality evaluation of the traditional Chinese medicine compound preparation.

The application discloses a tanshinone MAPK4 protein kinase and application of a coding gene thereof in regulating tanshinone content in Salvia miltiorrhiza. The application finds that the tanshinone MAPK4 protein kinase can improve gene transcription level and protein level of a key synthesis enzyme on a tanshinone synthesis path, and then improves tanshinone content (such as tanshinone IIA, dihydrotanshinone I, cryptotanshinone and tanshinone I) in Salvia miltiorrhiza. Therefore, the tanshinone MAPK4 protein kinase, the coding gene and an expression vector containing the coding gene can be used for regulating and improving tanshinone in Salvia miltiorrhiza.

The invention discloses a salvia miltiorrhiza quality evaluation method based on HPLC-DAD and multivariate analysis, and relates to the technical field of medicine quality evaluation, and the salvia miltiorrhiza quality evaluation method comprises the following steps: extracting effective components from salvia miltiorrhiza medicinal material samples collected from different regions by adopting an extraction solvent, the effective components at least comprise salvianic acid A sodium, rosmarinic acid, salvianolic acid B, cryptotanshinone, tanshinone I and tanshinone IIA, HPLC-DAD is adopted for chromatographic analysis, and the extracted effective components are subjected to multivariate statistical analysis. According to the system, the quality difference of salvia miltiorrhiza from different producing areas is evaluated, and scientific basis and data support are provided for standardized planting, producing area screening and clinical reasonable application of salvia miltiorrhiza medicinal materials.

The application discloses a kind of heart tonic tablet fingerprint spectrum detection methods, belong to traditional Chinese medicine detection technical field.The technical scheme includes: to system applicability solution, reference solution, medicinal material solution, test solution are detected by high performance liquid chromatography, obtain chromatogram;According to the chromatogram obtained in S5, determine the chemical composition of each chromatographic peak in the fingerprint spectrum, respectively 3 peaks of calycosin-7-glucoside, 4 peaks of 4-methoxy salicylaldehyde, 6 peaks of salvianolic acid B, 9 peaks of tanshinone I, 10 peaks of cryptotanshinone, 12 peaks of tanshinone IIA;According to the chromatogram obtained in S5, determine the source of each chromatographic peak in the fingerprint spectrum.The application is applied to heart tonic tablet detection aspect, solves the determination of only tanshinone IIA under the content item of existing heart tonic tablet current quality standard, control index is single, thus cannot comprehensively reflect the overall quality level of preparation problem, with the characteristics of accurate, stable and reliable detection result.

Disclosed is compound YM155, tanshinone I or cryptotanshinone, or a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, or a crystal form thereof, for treating and / or preventing diseases caused by coronavirus.

The application discloses a synchronous green extraction method of salvianolic acid B, tanshinone I, cryptotanshinone and tanshinone IIA in Danshen, which comprises the following steps: crushing Danshen into powder, and adding a bio-based solvent to the Danshen powder for ultrasonic-assisted extraction. When the extraction solvent is glycerol formal / acetic propionic acid (57.8 / 42.2, v / v), the liquid-solid ratio is 15 mL / g, the ultrasonic extraction temperature is 35 DEG C, the ultrasonic extraction time is 30 min, and the ultrasonic power is 360 W, the extraction rate of salvianolic acid B, tanshinone I, cryptotanshinone and tanshinone IIA in Danshen is 85.18 (mg / g), 0.347 (mg / g), 1.120 (mg / g) and 0.931 (mg / g) respectively, which is significantly higher than that of traditional methanol and ethanol. Therefore, the method provided by the application can effectively improve the extraction efficiency of salvianolic acid B, tanshinone I, cryptotanshinone and tanshinone IIA in Danshen, avoid the use of organic solvents such as methanol and ethanol, and is more green and environment-friendly.

This invention relates to an additive for NK cell induction and expansion culture, a culture medium, and their applications. The additive comprises tanshinone I and berberine. Specifically, PBMCs are isolated from human peripheral blood. On the third day of NK cell activation culture, tanshinone I (final concentration 0.1-10 µM) and berberine (final concentration 10-100 µM) are added to the culture system. Both tanshinone I and berberine are natural products with wide availability. Their combined use can significantly increase the proportion of memory NK cells, while exhibiting high viability, high purity, high expansion rate, and high cytotoxic activity. Flow cytometry analysis showed a significant increase in the positive expression rates of some NK cell markers, including CD62L, CD127, and Eomes.

The application discloses a method for determining the content of five components in Baiyu ointment based on a quantitative analysis of multiple components, and relates to the technical field of drug detection. ′ The method uses tanshinone II A as an internal standard for quantitative analysis of multiple components, establishes the relative correction factors of 1,4-di[4-(glucose oxygen) benzyl]-2-isobutyl malonic acid ester, tanshinone I, 6-gingerol, beta, beta The content of each component in the Baiyu ointment is calculated through the relative correction factors, and the specific steps include: preparation of a test sample solution; preparation of a reference sample solution; chromatographic conditions and system suitability test; determination and calculation. The application overcomes the single and one-sided quality control of the Baiyu ointment, and has important significance for further improving the quality control level of the Baiyu ointment, guaranteeing the clinical curative effect and improving the related evaluation system.

The invention discloses a tanshinone I intrauterine sustained-release medicament for treating gynecological tumors and application thereof, which is characterized in that tanshinone I is prepared into a nano-structure lipid carrier with the average particle size of 100-200nm, so that the water solubility and biological membrane permeability of the nano-structure lipid carrier are remarkably improved; and then the carrier is loaded in a biodegradable polymer slow-release rod which can be placed in a uterine cavity. The sustained-release rod can release drugs when the environment in the uterine cavity declines, and local, long-acting and targeted drug delivery to the focus part is achieved. An in-vitro cell experiment proves that the inhibiting effect of the preparation on hysteromyoma cells is obviously higher than the toxicity of the preparation on normal hysteromyoma cells, and the selectivity index is greater than 2; therefore, the problems of poor solubility of tanshinone I and weak systemic administration targeting are solved, and the tanshinone I has the outstanding advantages of high efficiency, low toxicity and good patient compliance.

The application discloses application of a Salvia miltiorrhiza SmPYL8 gene in regulating tanshinone content, and a nucleotide sequence of the Salvia miltiorrhiza SmPYL8 gene is shown as SEQ ID NO. 1. Specifically, the expression of the Salvia miltiorrhiza SmPYL8 gene is silenced or inhibited, so that the content of tanshinone in the hairy roots of Salvia miltiorrhiza is increased. The tanshinone is any one or two or more of tanshinone I, dihydrotanshinone I, tanshinone II A and cryptotanshinone. The application further discloses a method for increasing the content of tanshinone in the hairy roots of Salvia miltiorrhiza. It is found by the application that the Salvia miltiorrhiza SmPYL8 gene has a negative regulation effect on the synthesis and accumulation of tanshinone components, and silencing the gene can effectively increase the content of tanshinone components. The application has important reference value and significance for the cultivation of excellent varieties of Salvia miltiorrhiza.

The application discloses application of a Salvia miltiorrhiza SmPYL4 gene in regulating tanshinone content, and a nucleotide sequence of the Salvia miltiorrhiza SmPYL4 gene is shown as SEQ ID NO. 1. Specifically, the expression of the Salvia miltiorrhiza SmPYL4 gene is silenced or inhibited, so that the content of tanshinone in the hairy roots of Salvia miltiorrhiza is increased. The tanshinone is any one or two or more of tanshinone I, dihydrotanshinone I, tanshinone II A and cryptotanshinone. The application further discloses a method for increasing the content of tanshinone in the hairy roots of Salvia miltiorrhiza. The application finds that the Salvia miltiorrhiza SmPYL4 gene has a negative regulation effect on the synthesis and accumulation of tanshinone components, and silencing the gene can effectively increase the content of tanshinone components. The application has important reference value and significance for the cultivation of excellent varieties of Salvia miltiorrhiza.

The invention discloses a fingerprint detection method for tonifying and heart-strengthening tablets, and belongs to the technical field of traditional Chinese medicine detection. According to the technical scheme, the method comprises the following steps: performing high performance liquid chromatography detection on a system applicability solution, a reference substance solution, a medicinal material solution and a test solution to obtain chromatograms; s5, determining the chemical components of each chromatographic peak in the fingerprint spectrum according to the chromatogram obtained in S5, namely calycosin glucoside at the peak 3, 4-methoxysalicylaldehyde at the peak 4, salvianolic acid B at the peak 6, tanshinone I at the peak 9, cryptotanshinone at the peak 10 and tanshinone IIA at the peak 12; and determining the source of each chromatographic peak in the fingerprint spectrum according to the chromatogram obtained in the step S5. The method is applied to the detection of the tonifying and heart-strengthening tablets, solves the problem that the whole quality level of the preparation cannot be comprehensively reflected because only tanshinone IIA is determined and the control index is single under the content item of the current quality standard of the existing tonifying and heart-strengthening tablets, and has the characteristics of accurate detection result, stability and reliability.

The application belongs to the field of traditional Chinese medicines, and provides a method for constructing a kidney-strengthening tablet fingerprint spectrum, which comprises: detecting test sample solution and reference material solution by HPLC, wherein the chromatographic conditions are as follows: using octadecylsilane bonded silica gel as a filler; using acetonitrile as mobile phase A and 0.05% formic acid water as mobile phase B, and identifying 13 chromatographic peaks, which are 5-hydroxymethyl furfural, morroniside, motherwort alkaloid hydrochloride, loganin, pinoresinol di-glucoside, paeoniflorin, salvianolic acid B, psoralen, isopsoralen, paeonol, cryptotanshinone, tanshinone I and tanshinone IIA, so that the quality of the kidney-strengthening tablet can be comprehensively and accurately characterized. Meanwhile, the detection method in the application is stable and feasible. The characteristic spectrum established by the application can comprehensively reflect the complex chemical components and relative proportions of the kidney-strengthening tablet, and can effectively characterize the quality of the medicine.